Find Out If You Have a Case
Free, confidential review by Attorney Matthew T. Marin. Prefer to talk? Call (888) 348-2735.
Dupixent Lawsuit — Free, Confidential Case Review
Dupixent lawsuit help for Connecticut patients
Marin & Murphy is licensed in Connecticut. Two confidential minutes tells you whether you have a case.
ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · filing deadlines vary by state.
Were you — or someone you love — diagnosed with CTCL or another T-cell lymphoma after taking Dupixent?
Check if my case qualifiesfree · confidential · takes 2 minutes
I’m not sure of my exact diagnosis →
No documents needed · confidential · an answer either way · no fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.
Or talk to a person now: (888) 348-2735 — answered 24/7
Stefanie A. Murphy & Matthew T. Marin
Partners
Every Dupixent inquiry gets a personal review — and an honest answer either way, free and without obligation.
Claims are brought against Sanofi and Regeneron, the makers of Dupixent — not against your doctor. Conversations are confidential. Some matters may be referred to other lawyers. No settlement has been reached, and most cases are in their earliest stages; every case must be proven on its own facts. Attorney Advertising.
Marin & Murphy Law Firm is currently accepting Dupixent CTCL cases from Connecticut residents. The core criterion is a diagnosis of cutaneous T-cell lymphoma (CTCL) or a qualifying T-cell lymphoma subtype made during or after Dupixent (dupilumab) use — there is no minimum length of use, and families may bring a claim through the estate of a loved one who has died. A Connecticut case becomes part of the federal consolidation in MDL 3180 in the District of New Jersey.
This page is about a lawsuit — it is not medical advice, and filing a claim does not require you to stop taking Dupixent. Decisions about your medication belong with you and your doctor.
Lawsuits consolidated in MDL 3180 (D.N.J.) allege that Dupixent (dupilumab) is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn about it. No court has ruled on these allegations, no settlement exists, and the litigation is in its earliest stages. Published studies report a statistical association — which the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal it is still evaluating; Dupixent’s FDA label does not currently warn about lymphoma. Whether any individual has a claim depends on their medical records and the law of their state.
Is Marin & Murphy Accepting Dupixent CTCL Cases From Connecticut?
Yes. Both of the firm’s attorneys, Matthew T. Marin and Stefanie A. Murphy, are admitted to practice in Connecticut. The Dupixent lawsuit is not a class action but a set of individual claims consolidated for pretrial proceedings as MDL 3180, and a Connecticut resident’s claim is evaluated on its own records: the pathology report establishing the diagnosis, the pharmacy and treatment history establishing Dupixent use, and the dates connecting the two. Whether a claim is accepted is determined after review, and no attorney-client relationship is created until a written engagement agreement is signed.
Who Qualifies From Connecticut?
The criteria are national, not state-specific — the full detail, including all fourteen qualifying T-cell lymphoma subtypes, is set out on the who qualifies page. In short:
Dupixent Lawsuit Qualification Checklist
- You took Dupixent (dupilumab) — for any length of time; there is no minimum duration of use
- You were diagnosed with cutaneous T-cell lymphoma (CTCL) or a qualifying T-cell lymphoma subtype during or after your Dupixent use
- Claims may be brought for a family member who has died, through their estate
- You are not currently represented by another attorney or law firm for this claim
Free Confidential Evaluation — No Fee Unless There Is a Recovery
Call (888) 348-2735 or use the confidential case review form on this page.
Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.
Who Is Included in the Filed Dupixent Cases? — Connecticut
Every Dupixent CTCL lawsuit filed in federal court now proceeds in one place, MDL 3180 in the District of New Jersey, regardless of where the plaintiff lives. Public docket indexes do not reliably show which member cases were brought by Connecticut residents: most complaints in the MDL are not available in the free public record, and the court a case was filed in says little about the plaintiff’s home state. Rather than guess, this page states what the record supports. The MDL 3180 tracker carries the current case count, how it is counted, and the latest docket activity; when a Connecticut resident’s complaint becomes publicly available, this section will describe it. Marin & Murphy Law Firm is licensed in Connecticut and reviews Dupixent CTCL claims from Connecticut residents directly; the criteria are described on do I qualify.
Where Would a Connecticut Dupixent Case Be Filed?
Connecticut has one federal district court: the United States District Court for the District of Connecticut. No Dupixent CTCL lawsuit filed there proceeds alone — the Judicial Panel on Multidistrict Litigation has centralized these cases as MDL 3180 before Judge Zahid N. Quraishi in the United States District Court for the District of New Jersey, so a Connecticut case is transferred to the MDL for coordinated pretrial proceedings — or, where the MDL court’s case-management orders permit, filed in the District of New Jersey directly. Either route leads to the same consolidated proceeding, and your case remains an individual claim; an MDL is not a class action.
What Is the Filing Deadline for a Connecticut Dupixent Claim?
Connecticut law sets more than one limitations period that could bear on a Dupixent CTCL claim, and which period governs depends on the legal theory pleaded and on when the claim is treated as having accrued. Because different rules produce different deadlines, this page does not state a single figure — stating one would be less accurate, not more. The timing analysis is case-specific, and running it against your records is part of the free evaluation.
Connecticut’s Product Liability Act gives claimants three years from when the injury is first sustained or discovered, or reasonably should have been discovered, under Conn. Gen. Stat. § 52-577a — subject to a ten-year repose rule that carries its own exceptions, including harm occurring within the product’s useful safe life. How those layers interact for a specific diagnosis is a lawyer’s analysis built on real dates, and because Marin & Murphy Law Firm attorneys are licensed in Connecticut, that analysis can be done directly.
A wrongful-death claim must be brought within two years of death (and no more than five years from the act) by the executor or administrator of the estate (Conn. Gen. Stat. § 52-555(a)).
How Common Is CTCL in Connecticut?
Connecticut is home to about 3.7 million people (U.S. Census Bureau, 2024 estimate). Cutaneous T-cell lymphoma is rare — roughly 8.55 new cases per million person-years (SEER) — which works out to on the order of 30 new CTCL diagnoses across Connecticut in a typical year. That rarity is exactly why a diagnosis deserves an individual look: statistics do not decide any single claim, and your medical records are what a review actually reads.
Free Confidential Evaluation — No Fee Unless There Is a Recovery
Call (888) 348-2735 or use the confidential case review form on this page.
Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.
Prefer to start online? The free case review takes about two minutes and asks only what the criteria turn on: your diagnosis, your Dupixent use, and their timing.
Connecticut Dupixent Lawsuit FAQs
Is Marin & Murphy accepting Dupixent CTCL cases from Connecticut?
Yes. Marin & Murphy Law Firm is currently accepting Dupixent CTCL cases from Connecticut residents. The evaluation is free and confidential, and no attorney-client relationship is created until a written engagement agreement is signed.
Who qualifies to file from Connecticut?
The criteria are the same nationally: a diagnosis of cutaneous T-cell lymphoma or a qualifying T-cell lymphoma subtype during or after Dupixent use, with no minimum duration of use. Claims may also be brought through the estate of a family member who has died.
Where would a Connecticut Dupixent case actually be filed?
Connecticut’s federal court is the United States District Court for the District of Connecticut. Federal Dupixent CTCL cases are centralized in MDL 3180 in the District of New Jersey, so a Connecticut case is transferred there — or filed there directly where permitted — for coordinated pretrial proceedings, and it remains an individual claim throughout.
What is the deadline to file a Connecticut Dupixent claim?
Deadlines come from Connecticut statutes of limitation and related doctrine — the section above covers the framework. How it applies depends on the dates in your records, and reviewing them is part of the free evaluation.
What does it cost to bring a claim?
Representation is on a contingency basis: no fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery; you are not responsible for them if there is no recovery, unless a court directs otherwise.
Has a court ruled that Dupixent causes CTCL? Is there a settlement?
No and no. Plaintiffs allege an association; published studies report a statistical association their authors note does not establish causation; the FDA is still evaluating a potential signal; and no settlement exists.
Do I have to stop taking Dupixent to file?
No. Filing a claim does not require you to stop taking Dupixent. Decisions about your medication belong with you and your doctor; this is a lawsuit question, not a medical one.
What is MDL 3180?
MDL 3180 is the federal multidistrict litigation consolidating Dupixent CTCL lawsuits for pretrial proceedings in the United States District Court for the District of New Jersey, before Judge Zahid N. Quraishi. Cases are coordinated for efficiency but remain individual claims — an MDL is not a class action.
Nearby states
Dupixent Use in Connecticut: What the Public Data Shows
Prescribers across Connecticut rely on Dupixent (dupilumab) for atopic dermatitis and several other inflammatory conditions. Federal drug-utilization records show how widely the medication is used in the state:
Connecticut saw its reported Medicaid prescription count grow by about 13% between 2024 and 2025. These figures cover Medicaid outpatient utilization only — they do not include prescriptions paid through Medicare or private insurance, so the total number of residents of Connecticut using Dupixent is higher. Totals exclude a small number of records the program suppresses for privacy.
Sources: Centers for Medicare & Medicaid Services, State Drug Utilization Data 2024 and 2025 (accessed August 21, 2026); In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, JPML Transfer Order, Schedule A (June 4, 2026). Utilization data reflects prescriptions reported by state Medicaid programs and is not evidence that any individual prescription caused injury.
Sources
- U.S. Judicial Panel on Multidistrict Litigation, Pending MDL Dockets by MDL Number (August 3, 2026) — jpml.uscourts.gov
- MDL 3180 docket records — CourtListener dockets 72288297 (JPML) and 73443394 (D.N.J. 3:26-md-03180), reviewed September 15, 2026.
- U.S. Census Bureau, Vintage 2024 Population Estimates (NST-EST2024), resident population as of July 1, 2024.
- SEER program data: cutaneous T-cell lymphoma incidence ≈8.55 cases per million person-years.
Attorney admissions: Matthew T. Marin — RI, CT, MA, SC, U.S.D.C. D.R.I. · Stefanie A. Murphy — RI, CT, MA, U.S.D.C. D.R.I./D.Conn./D.Mass.
Attorney Advertising.
Attorney Advertising. This page is for general information and is not legal advice; reading it does not create an attorney-client relationship, and no attorney-client relationship is formed until a written engagement agreement is signed. Marin & Murphy Law Firm attorneys are licensed in Rhode Island, Connecticut, Massachusetts, and South Carolina; the firm’s mass-tort practice is directed from its Charleston, South Carolina office. Responsible attorney: Matthew T. Marin, 997 Morrison Drive, Suite 200, Charleston, SC 29403. Cases may be handled together with co-counsel; whether a claim is accepted is determined after review. No representation is made that the quality of legal services is greater than that of other lawyers. Prior results do not guarantee a similar outcome; every case depends on its own facts.